Ascendis Pharma ADR (ASND) Stock Price, Quote & News

Company Profile

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candid...

Industry: Biotechnology

Sector: Healthcare

Phone: 45 70 22 22 44

Website: ascendispharma.com

Address:

Tuborg Boulevard 12, Hellerup, Denmark

gabbs Dec. 4 at 6:00 PM

$ASND interesting. Added to watch list

0 · Reply

BillionerOfKing Dec. 3 at 10:46 PM

$ASND Current Stock Price: $200.28 Contracts to trade: $200 ASND Dec 19 2025 Call Entry: $5.80 Exit: $8.79 ROI: 52% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Hognose Dec. 2 at 3:47 PM

$RYTM $ASND

0 · Reply

AStrokeOfLuck Nov. 28 at 3:33 PM

$ASND

0 · Reply

Tjcmd Nov. 27 at 1:41 PM

$ASND FYI…buy the dip? Doesn’t seem like a major setback

1 · Reply

knowthyself Nov. 26 at 1:08 AM

$ASND PDUFA extended 3 months.

0 · Reply

tradeitbetit Nov. 24 at 9:42 PM

$ASND so… is this getting approval? Odds? Upside or downside?

1 · Reply

JarvisFlow Nov. 18 at 1:55 PM

Wedbush has updated their rating for Ascendis Pharma ( $ASND ) to Outperform with a price target of 220.

0 · Reply

Dieseld28 Nov. 17 at 10:41 PM

$ASND Results of Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) in Children with Achondroplasia Published in JAMA Pediatrics https://finance.yahoo.com/news/results-pivotal-approach-trial-transcon-210100702.html

0 · Reply

SweepCastApp Nov. 17 at 10:33 PM

$ASND: Unusual Options Activity Alerted PUT flow observed 154x contracts at Strike price of $210 Exp on 12/19/2025 with Premium of $167K and showing BULLISH Sentiment

0 · Reply

Ascendis Pharma Hit By FDA Delay As TransCon CNP Decision Slips To 2026

Nov 25, 2025, 6:21 PM EST - 9 days ago

US FDA extends review of Ascendis Pharma's therapy for children with dwarfism

Nov 25, 2025, 6:15 PM EST - 9 days ago

Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia

Nov 17, 2025, 4:01 PM EST - 17 days ago

Results of Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) in Children with Achondroplasia Published in JAMA Pediatrics

Nov 12, 2025, 9:01 PM EST - 22 days ago

Ascendis Pharma A/S (ASND) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 4:01 PM EST - 22 days ago

Ascendis Pharma Reports Third Quarter 2025 Financial Results

Nov 12, 2025, 7:14 AM EST - 22 days ago

Ascendis Pharma Likely To Report Narrower Q3 Loss; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Nov 7, 2025, 8:30 AM EST - 27 days ago

New Pooled 3-Year Analysis Confirms Sustained, Clinically Meaningful Improvements in Renal Function for TransCon® PTH (Palopegteriparatide)-Treated Adults with Hypoparathyroidism

Nov 5, 2025, 4:01 PM EST - 4 weeks ago

Ascendis Pharma to Report Third Quarter 2025 Financial Results and Provide Business Update on November 12, 2025

Nov 3, 2025, 4:01 PM EST - 4 weeks ago

3-Year Renal Data in Adults with Hypoparathyroidism Treated with TransCon® PTH (Palopegteriparatide) to Be Shared at Kidney Week 2025

Nov 3, 2025, 9:58 AM EST - 4 weeks ago

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

ABBV ALNY AMGN BMY LLY MBX MDGL

Oct 8, 2025, 4:01 PM EDT - 2 months ago

Ascendis Submits Marketing Authorisation Application to the European Medicines Agency for TransCon® CNP for Treatment of Children with Achondroplasia

Sep 2, 2025, 4:01 PM EDT - 3 months ago

Ascendis to Share Latest Endocrinology Rare Disease Data in 3 Oral Presentations at ASBMR 2025

Aug 28, 2025, 4:01 PM EDT - 3 months ago

Ascendis Pharma to Participate in the 2025 Wells Fargo Healthcare Conference

Aug 9, 2025, 2:46 AM EDT - 4 months ago

Ascendis Pharma A/S (ASND) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:01 PM EDT - 4 months ago

Ascendis Pharma Reports Second Quarter 2025 Financial Results

Jul 31, 2025, 4:01 PM EDT - 4 months ago

Ascendis Pharma to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025

Jul 28, 2025, 7:00 AM EDT - 4 months ago

FDA Approves SKYTROFA® (Lonapegsomatropin-tcgd) for the Once-Weekly Treatment of Adults with Growth Hormone Deficiency

Jul 14, 2025, 4:01 PM EDT - 5 months ago

New 3-Year Phase 3 Data Confirmed Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism, Including Improvements in Biochemistries, Kidney Function, and Quality of Life

Jul 7, 2025, 4:01 PM EDT - 5 months ago

Ascendis to Share Its Latest Endocrinology Rare Disease Data at ENDO 2025

Jun 9, 2025, 7:00 AM EDT - 6 months ago

TransCon® hGH Boosted Treatment Benefits of TransCon® CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COACH Trial

Jun 2, 2025, 8:00 AM EDT - 6 months ago

FDA Accepts TransCon® CNP NDA for Priority Review

May 20, 2025, 6:00 AM EDT - 7 months ago

Cerrado Gold and Ascendant Resources Announce Completion of Business Combination Transaction

May 13, 2025, 4:01 PM EDT - 7 months ago

New Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon® CNP (Navepegritide)

May 12, 2025, 4:45 PM EDT - 7 months ago

New 4-Year Data Shows Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism

May 5, 2025, 8:30 AM EDT - 7 months ago

Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE & ESE 2025

May 1, 2025, 9:35 PM EDT - 7 months ago

Ascendis Pharma A/S (ASND) Q1 2025 Earnings Call Transcript

May 1, 2025, 4:01 PM EDT - 7 months ago

Ascendis Pharma Reports First Quarter 2025 Financial Results

Apr 24, 2025, 4:01 PM EDT - 8 months ago

Ascendis Pharma to Report First Quarter 2025 Financial Results and Provide Business Update on May 1, 2025

Apr 14, 2025, 4:38 PM EDT - 8 months ago

Ascendis Pharma: Rare Disease Player Is A Buy On Yorvipath Launch Trajectory

Mar 31, 2025, 4:01 PM EDT - 8 months ago

Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia

Feb 24, 2025, 4:01 PM EST - 10 months ago

Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care Conference

Feb 13, 2025, 2:40 PM EST - 10 months ago

Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday?

Feb 12, 2025, 11:03 PM EST - 10 months ago

Ascendis Pharma A/S (ASND) Q4 2024 Earnings Call Transcript

Feb 12, 2025, 4:05 PM EST - 10 months ago

Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs

Feb 12, 2025, 4:01 PM EST - 10 months ago

Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 5, 2025, 4:01 PM EST - 10 months ago

Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025

Jan 29, 2025, 11:25 AM EST - 11 months ago

Ascendis-Novo Weight Loss Deal Highlights Technology Platform, Signals Growth Potential (Rating Upgrade)

Jan 29, 2025, 12:31 AM EST - 11 months ago

Ascendis Pharma: Danish Blockbuster Hunter

Jan 12, 2025, 5:00 PM EST - 11 months ago

Ascendis Pharma Provides Business and Strategic Roadmap Update at 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 8:30 AM EST - 11 months ago

Ascendis Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Dec 19, 2024, 8:30 AM EST - 1 year ago

YORVIPATH® (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in Adults

Dec 16, 2024, 8:30 AM EST - 1 year ago

New InsiGHTS Trial of TransCon™ hGH (Lonapegsomatropin) in Turner Syndrome Achieved Primary Objective at Week 26

Dec 12, 2024, 4:01 PM EST - 1 year ago

FDA Accepts Ascendis Pharma's Supplemental Biologics License Application for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency

Dec 10, 2024, 7:00 AM EST - 1 year ago

Er-Kim Extends Exclusive Distribution Agreement with Ascendis Pharma A/S to Expand Commercialization of Its Endocrinology Portfolio to Eurasian Markets

Nov 14, 2024, 10:53 PM EST - 1 year ago

Ascendis Pharma A/S (ASND) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 4:01 PM EST - 1 year ago

Ascendis Pharma Reports Third Quarter 2024 Financial Results

Sep 30, 2024, 8:30 AM EDT - 1 year ago

Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency

Sep 30, 2024, 8:30 AM EDT - 1 year ago

New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide) Presented at ASBMR 2024

Sep 19, 2024, 8:16 PM EDT - 1 year ago

Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs

gabbs Dec. 4 at 6:00 PM

$ASND interesting. Added to watch list

0 · Reply

BillionerOfKing Dec. 3 at 10:46 PM

0 · Reply

Hognose Dec. 2 at 3:47 PM

$RYTM $ASND

0 · Reply

AStrokeOfLuck Nov. 28 at 3:33 PM

$ASND

0 · Reply

Tjcmd Nov. 27 at 1:41 PM

$ASND FYI…buy the dip? Doesn’t seem like a major setback

1 · Reply

knowthyself Nov. 26 at 1:08 AM

$ASND PDUFA extended 3 months.

0 · Reply

tradeitbetit Nov. 24 at 9:42 PM

$ASND so… is this getting approval? Odds? Upside or downside?

1 · Reply

JarvisFlow Nov. 18 at 1:55 PM

Wedbush has updated their rating for Ascendis Pharma ( $ASND ) to Outperform with a price target of 220.

0 · Reply

Dieseld28 Nov. 17 at 10:41 PM

0 · Reply

SweepCastApp Nov. 17 at 10:33 PM

$ASND: Unusual Options Activity Alerted PUT flow observed 154x contracts at Strike price of $210 Exp on 12/19/2025 with Premium of $167K and showing BULLISH Sentiment

0 · Reply

BEATOFtheMARKET Nov. 17 at 4:58 PM

LIST 11/14 TO 11/28 FIRST DAY $ASND

0 · Reply

WAJeff Nov. 17 at 4:20 PM

$ASND $220.99 ath

0 · Reply

Pika_Capital Nov. 17 at 2:52 PM

$ASND whoah

2 · Reply

BEATOFtheMARKET Nov. 16 at 10:41 PM

$ARKQ $ASB $ASML $ASND $ASPI

0 · Reply

OptionRunners Nov. 14 at 7:35 PM

$ASND Buyer of the April 17th 2026 $250 calls 1,000 times for $10.80

0 · Reply

WAJeff Nov. 14 at 4:38 PM

$ASND $219.30 ath

0 · Reply

Pika_Capital Nov. 14 at 3:29 PM

$ASND beautiful. And clowns were selling on Wed after hours for $185 😂

0 · Reply

TrendEdgeLogan Nov. 13 at 10:21 PM

$ASND monster weekly bar and volume. $400 in due time. I'm along for the ride

1 · Reply

TrendEdgeLogan Nov. 13 at 10:20 PM

I can still $SPOT several reasons that you $CNTA call $ONC 'le $INTA the $ASND 'ing seasonal tailwinds

0 · Reply

JFais Nov. 13 at 6:41 PM

"I wonder when Danish $NVO will offer to buy $ASND (also Danish), so $PFE could enter just to raise the final price for $NVO as a revenge"

1 · Reply

ethan_r25 Nov. 13 at 6:26 PM

$ASND You want your edge? Here it is. NXXT: $2/share 196% YoY growth 3.38× sales Energy + AI + federal tailwind 48 institutional holders Earnings in 48 hours This isn’t ""maybe someday."" This is now. I’m positioned before the ER because afterward it won’t look cheap — it’ll look obvious.

0 · Reply

harper_t55 Nov. 13 at 3:56 PM

$ASND I am holding NXXT as the report could be today and funds buy since YoY growth plus margin progress does not deserve a low multiple and I want to be in before the street re marks the tape with BlackRock 582,422 and Charles Schwab 43,770

0 · Reply

Market Cap	12.47B
Revenue (ttm)	393.50M
Net Income (ttm)	-409.12M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-103.97%
Debt to Equity Ratio	-4.67

Volume	674,900
Avg Vol	502,700
Day's Range	N/A - N/A
Shares Out	61.70M
Stochastic %K	11%
Beta	0.45
Analysts	Strong Sell
Price Target	$258.12